Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas

Launched by MING-YUAN CHEN · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to screen for nasopharyngeal carcinoma (NPC), a type of cancer that can be linked to the Epstein-Barr virus (EBV). Researchers want to find out if testing blood for EBV DNA or specific antibodies (called P85-Ab) is better at detecting NPC than the current standard test, which checks for two different antibodies. They will compare two methods: one where people first get tested for the antibodies and, if positive, move on to a blood test, and another where all tests are done at once. The goal is to make screening more efficient, reduce the number of invasive procedures like biopsies, and lower medical costs.

To participate in this trial, individuals must be between 30 and 69 years old, live in Guangdong or Guangxi Province, and be able to commit to long-term follow-up. They should also be in good health without severe medical issues or current cancers. Participants will provide consent to join the study, get tested for EBV-related biomarkers, and may undergo additional examinations if they test positive. This research aims to improve early detection of NPC, which is crucial for better treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Voluntarily signed informed consent.
• • Age between 30 and 69 years at the time of screening.
• • Residents of Guangdong Province or Guangxi Province.
• • Able to cooperate with long-term follow-up.
• Exclusion Criteria:
• • Severe medical comorbidities, significant organ (heart, lung, liver, kidney) dysfunction, or psychiatric disorders.
• • Severe autoimmune diseases or immunodeficiency.
• • History of or current malignant tumors.
• • Inability to cooperate with the study due to psychological, social, familial, or geographical reasons.